Science & Technology
Human T Cell Lymphotropic Virus Vaccine Development
Department of Health and Human Services — National Institutes of Health
Opportunity #: 9R42CA290612-03
Award Ceiling
$1000K
Award Floor
$1000K
Close Date
Aug 31, 2026
169 days leftTotal Funding
$1000K
Expected Awards
1
Posted Date
Sep 1, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-9R42CA290612-03
Description
STTR Phase Phase II award: "Human T Cell Lymphotropic Virus Vaccine Development" awarded to STINGINN, LLC in Miami, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $999,969. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.